Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Doxycycline Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP7 known ✓ | P09237 | 1/20 | 0.70 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.70 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.70 |
| ▸ | MMP2 | P08253 | 1/20 | 0.70 |
| ▸ | MMP3 | P08254 | 1/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.69 |
| ▸ | USP2 | O75604 | 6/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.68 |
| ▸ | RECQL | P46063 | 7/20 | 0.65 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.65 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxycycline Anhydrous SCHEMBL3155 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL29545414 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL41884 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL11417262 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL3680869 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL41883 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL28250743 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL11417256 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL8683380 | 1.00 | MMP2 (0.70) | MMP2MMP3MMP7MMP8ADORA1 | |
| Doxycycline Anhydrous SCHEMBL497163 | 0.99 | TDP1 (0.69) | MMP2MMP3MMP7MMP8ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102813665-A | Composition for synergy of doxycycline antibacterial activity and application thereof | SHANGHAI RUICHUANG MEDICAL TECHNOLOGY CO LTD | 2012-12-12 | — | — | CN | claimed |
| WO-2021074598-A1 | COMBINATION OF ZIDOVUDINE WITH A TETRACYCLINE ANTIBIOTIC | HELPERBY THERAPEUTICS LIMITED (GB) | 2021-04-22 | — | — | WO | disclosed |
| CN-111818927-A | Minocycline for treating inflammatory skin diseases | 雷迪博士实验室有限公司 | 2020-10-23 | — | — | CN | disclosed |
| EP-3200749-B1 | COMPOSITIONS FOR THE TREATMENT OF PERI-IMPLANTITIS | POLYPID LTD (IL) | 2020-09-02 | — | — | EP | disclosed |
| US-10758639-B2 | Methods for the treatment of peri-implantitis | POLYPID LTD. (IL) | 2020-09-01 | — | — | US | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3655104-A1 | AN OSTEOADSORPTIVE FLUOROGENIC SUBSTRATE OF CATHEPSIN K FOR IMAGING OSTEOCLAST ACTIVITY AND MIGRATION | The Regents of the University of California (US) | 2020-05-27 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019018238-A1 | AN OSTEOADSORPTIVE FLUOROGENIC SUBSTRATE OF CATHEPSIN K FOR IMAGING OSTEOCLAST ACTIVITY AND MIGRATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-01-24 | — | — | WO | disclosed |
| CN-109010916-A | Containing the mouldable preparation of aerobic sterol in acellular tissue matrices | 华沙整形外科股份有限公司 | 2018-12-18 | — | — | CN | disclosed |
| US-20080021040-A1 | Method and composition for treating periodontal disease | REGENA THERAPEUTICS, LC | 2008-01-24 | — | — | US | disclosed |
| US-7241746-B2 | Method and composition for treating periodontal disease | REGENA THERAPEUTICS, LC (US) | 2007-07-10 | — | — | US | disclosed |
| CN-1883461-A | Sustained-releasing oral mucosa medicinal film | HE YUAN (CN) | 2006-12-27 | — | — | CN | disclosed |
| WO-2005023193-A2 | METHODS OF TREATING ENDOMETRIOSIS | INTERLEUKIN GENETICS, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005013900-A2 | METHOD AND COMPOSITION FOR TREATING PERIDONTAL DISEASE | REGENA THERAPEUTICS LC (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20050032720-A1 | Method and composition for treating peridontal disease | REGENACORP, INC. | 2005-02-10 | — | — | US | disclosed |
| US-20040014024-A1 | Screening assay for antagonists of FGFR-mediated malignant cell transformation and tumor formation | YAYON AVNER (IL) | 2004-01-22 | — | — | US | disclosed |
| EP-1164838-A4 | SCREENING ASSAY FOR ANTAGONISTS OF FGFR-MEDIATED MALIGNANT CELL TRANSFORMATION AND TUMOR FORMATION | YEDA RES & DEV (IL) | 2002-06-19 | — | — | EP | disclosed |
| EP-1164838-A2 | SCREENING ASSAY FOR ANTAGONISTS OF FGFR-MEDIATED MALIGNANT CELL TRANSFORMATION AND TUMOR FORMATION | YEDA RESEARCH AND DEVELOPMENT CO., Ltd. (IL) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000046343-A2 | SCREENING ASSAY FOR ANTAGONISTS OF FGFR-MEDIATED MALIGNANT CELL TRANSFORMATION AND TUMOR FORMATION | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032720-A1 | Method and composition for treating peridontal disease | DNM2, CD68, PGF | MMP7 145/4885MMP8 169/4885MMP13 182/4885 |
| US-20080021040-A1 | Method and composition for treating periodontal disease | CD68, AMPD2, PGF | MMP7 487/4885MMP8 190/4885MMP13 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.